ARTICLE | Finance
Cyteir synthetic lethality compound prompts Novo to lead $40M investment
Cyteir is Novo Holdings’ first investment in the DNA damage repair space
October 15, 2019 11:53 PM UTC
Updated on Nov 13, 2019 at 9:38 PM UTC
After bringing its lead candidate to the clinic, Cyteir raised $40.2 million in a series B extension to propel the first-in-class RAD51 inhibitor to clinical proof of concept and enable the development of a second synthetic lethality candidate.
Tuesday’s raise brings the round’s total to $75.2 million, more than a year after the first close...
BCIQ Target Profiles